About Psychedelic-Assisted Therapy
Psychedelic-assisted therapy encompasses a broad spectrum of substances, including those that are inherently psychedelic, like psilocybin found in "magic mushrooms", LSD, mescaline (in peyote) or DMT (the active chemical in ayahuasca) as well as those with psychedelic-like properties such as ketamine or MDMA. While some substances are well-researched and have a historical context dating back to the mid-20th century when they were explored for their therapeutic potential, others have faced stigmatization and legal restrictions that limited research and therapeutic use.
​
LSD, for example, gained notoriety during the counterculture movement of the 1960s, leading to its stigmatization and classification as a Schedule I controlled substance in many countries, making research and therapeutic use difficult. Psilocybin, the psychoactive compound in magic mushrooms, shares a similar historical trajectory, facing legal restrictions that hindered research and therapeutic applications. However, there has been a growing movement to decriminalize or legalize psilocybin in some regions, fostering renewed research into its therapeutic potential. At this time, the use of these substances for therapeutic purposes remains illegal in the state of Connecticut.
Ketamine and MDMA, while not considered classic psychedelics, have shown promise in treating conditions like depression, anxiety and PTSD. Ketamine has gained FDA approval for use in specific therapeutic contexts, and MDMA is currently undergoing clinical trials, indicating a more favorable shift in the legal and scientific landscape surrounding these substances.
"What we achieve inwardly will change outer reality." - Plutarch
Integration and Harm Reduction
Harm reduction in the context of psychedelic care and integration refers to a set of principles and practices aimed at minimizing potential risks and negative outcomes associated with the use of psychedelics. While psychedelics can offer profound therapeutic benefits, they also carry inherent risks, especially when used improperly or without guidance. Harm reduction strategies are designed to ensure the safety and well-being of individuals engaging in psychedelic experiences.
​
The 3 stages of psychedelic-assisted therapy are: 1. Preparation 2. Support and guidance during the session (sitting) 3. Integration
​
A therapist plays a crucial role in harm reduction by providing a structured and safe environment for psychedelic sessions. They help clients assess their readiness for the experience, conducting thorough screenings to identify any contraindications or potential risks. Therapists also offer education and guidance on proper dosage, set, and setting to optimize the safety and effectiveness of the journey. During the psychedelic experience itself, therapists are on hand to provide emotional support, helping individuals navigate challenging or overwhelming moments to reduce the risk of psychological harm.
​
The therapist assists with post-session integration, which is a critical aspect of harm reduction. They help clients process and make sense of their experiences, addressing any residual psychological or emotional effects that may arise. By working with clients to integrate the insights and lessons learned during their psychedelic journeys into their daily lives, therapists ensure that the experience leads to positive and lasting changes while minimizing potential harm or confusion. In this way, therapists are essential in promoting the responsible and therapeutic use of psychedelics, ensuring that the benefits are maximized while the risks are minimized.